These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11624 related articles for article (PubMed ID: 11561695)
1. Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium. Margolin K; Longmate J; Synold TW; Gandara DR; Weber J; Gonzalez R; Johansen MJ; Newman R; Baratta T; Doroshow JH Invest New Drugs; 2001; 19(4):335-40. PubMed ID: 11561695 [TBL] [Abstract][Full Text] [Related]
2. Phase II trial of dolastatin-10 in patients with advanced breast cancer. Perez EA; Hillman DW; Fishkin PA; Krook JE; Tan WW; Kuriakose PA; Alberts SR; Dakhil SR Invest New Drugs; 2005 Jun; 23(3):257-61. PubMed ID: 15868383 [TBL] [Abstract][Full Text] [Related]
3. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Pitot HC; McElroy EA; Reid JM; Windebank AJ; Sloan JA; Erlichman C; Bagniewski PG; Walker DL; Rubin J; Goldberg RM; Adjei AA; Ames MM Clin Cancer Res; 1999 Mar; 5(3):525-31. PubMed ID: 10100703 [TBL] [Abstract][Full Text] [Related]
4. Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Kindler HL; Tothy PK; Wolff R; McCormack RA; Abbruzzese JL; Mani S; Wade-Oliver KT; Vokes EE Invest New Drugs; 2005 Oct; 23(5):489-93. PubMed ID: 16133801 [TBL] [Abstract][Full Text] [Related]
5. Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer. Saad ED; Kraut EH; Hoff PM; Moore DF; Jones D; Pazdur R; Abbruzzese JL Am J Clin Oncol; 2002 Oct; 25(5):451-3. PubMed ID: 12393982 [TBL] [Abstract][Full Text] [Related]
6. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Madden T; Tran HT; Beck D; Huie R; Newman RA; Pusztai L; Wright JJ; Abbruzzese JL Clin Cancer Res; 2000 Apr; 6(4):1293-301. PubMed ID: 10778954 [TBL] [Abstract][Full Text] [Related]
7. Activity of the dolastatin analogue, LU103793, in malignant melanoma. Smyth J; Boneterre ME; Schellens J; Calvert H; Greim G; Wanders J; Hanauske A; Ann Oncol; 2001 Apr; 12(4):509-11. PubMed ID: 11398885 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Vaishampayan U; Glode M; Du W; Kraft A; Hudes G; Wright J; Hussain M Clin Cancer Res; 2000 Nov; 6(11):4205-8. PubMed ID: 11106233 [TBL] [Abstract][Full Text] [Related]
9. Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. Aherne GW; Hardcastle A; Valenti M; Bryant A; Rogers P; Pettit GR; Srirangam JK; Kelland LR Cancer Chemother Pharmacol; 1996; 38(3):225-32. PubMed ID: 8646796 [TBL] [Abstract][Full Text] [Related]
10. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors. Ebbinghaus S; Rubin E; Hersh E; Cranmer LD; Bonate PL; Fram RJ; Jekunen A; Weitman S; Hammond LA Clin Cancer Res; 2005 Nov; 11(21):7807-16. PubMed ID: 16278403 [TBL] [Abstract][Full Text] [Related]
11. A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. Hoffman MA; Blessing JA; Lentz SS; Gynecol Oncol; 2003 Apr; 89(1):95-8. PubMed ID: 12694660 [TBL] [Abstract][Full Text] [Related]
12. Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc. Turner T; Jackson WH; Pettit GR; Wells A; Kraft AS Prostate; 1998 Feb; 34(3):175-81. PubMed ID: 9492845 [TBL] [Abstract][Full Text] [Related]
13. A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion. Supko JG; Lynch TJ; Clark JW; Fram R; Allen LF; Velagapudi R; Kufe DW; Eder JP Cancer Chemother Pharmacol; 2000; 46(4):319-28. PubMed ID: 11052630 [TBL] [Abstract][Full Text] [Related]
14. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses. Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542 [TBL] [Abstract][Full Text] [Related]
15. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules. Bai R; Friedman SJ; Pettit GR; Hamel E Biochem Pharmacol; 1992 Jun; 43(12):2637-45. PubMed ID: 1632820 [TBL] [Abstract][Full Text] [Related]
16. Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification. Kalemkerian GP; Ou X; Adil MR; Rosati R; Khoulani MM; Madan SK; Pettit GR Cancer Chemother Pharmacol; 1999; 43(6):507-15. PubMed ID: 10321512 [TBL] [Abstract][Full Text] [Related]
17. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1. Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595 [TBL] [Abstract][Full Text] [Related]
18. A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer. Marks RS; Graham DL; Sloan JA; Hillman S; Fishkoff S; Krook JE; Okuno SH; Mailliard JA; Fitch TR; Addo F Am J Clin Oncol; 2003 Aug; 26(4):336-7. PubMed ID: 12902880 [TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies. Villalona-Calero MA; Baker SD; Hammond L; Aylesworth C; Eckhardt SG; Kraynak M; Fram R; Fischkoff S; Velagapudi R; Toppmeyer D; Razvillas B; Jakimowicz K; Von Hoff DD; Rowinsky E J Clin Oncol; 1998 Aug; 16(8):2770-9. PubMed ID: 9704730 [TBL] [Abstract][Full Text] [Related]
20. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Bai R; Pettit GR; Hamel E Biochem Pharmacol; 1990 Jun; 39(12):1941-9. PubMed ID: 2353935 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]